Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

About Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:KERX
  • CUSIP: 49251510
  • Web:
  • Market Cap: $790.72 million
  • Outstanding Shares: 108,467,000
Average Prices:
  • 50 Day Moving Avg: $6.98
  • 200 Day Moving Avg: $6.05
  • 52 Week Range: $4.03 - $8.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -31.70
  • P/E Growth: -0.09
Sales & Book Value:
  • Annual Revenue: $36.98 million
  • Price / Sales: 21.38
  • Book Value: ($0.21) per share
  • Price / Book: -34.71
  • EBIDTA: ($121,500,000.00)
  • Net Margins: -387.12%
  • Return on Equity: -1,122.28%
  • Return on Assets: -88.17%
  • Debt-to-Equity Ratio: -5.55%
  • Current Ratio: 5.39%
  • Quick Ratio: 4.82%
  • Average Volume: 1.51 million shs.
  • Beta: 5.26
  • Short Ratio: 11.8
Frequently Asked Questions for Keryx Biopharmaceuticals (NASDAQ:KERX)

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) posted its earnings results on Thursday, May, 4th. The company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.03. The company had revenue of $11.82 million for the quarter, compared to analysts' expectations of $10.19 million. Keryx Biopharmaceuticals had a negative net margin of 387.12% and a negative return on equity of 1,122.28%. The firm's quarterly revenue was up 73.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.39) EPS. View Keryx Biopharmaceuticals' Earnings History.

Where is Keryx Biopharmaceuticals' stock going? Where will Keryx Biopharmaceuticals' stock price be in 2017?

9 brokers have issued twelve-month price objectives for Keryx Biopharmaceuticals' stock. Their predictions range from $7.00 to $10.00. On average, they expect Keryx Biopharmaceuticals' stock price to reach $8.60 in the next year. View Analyst Ratings for Keryx Biopharmaceuticals.

What are analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:

  • 1. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)
  • 2. According to Zacks Investment Research, "Keryx intends to focus on the growth of Auryxia in the U.S. dialysis market. Meanwhile, the company’s label expansion efforts on Auryxia in the iron-deficiency anemia (IDA) indication seem to be encouraging, given that the IDA market holds great potential. The FDA accepted for review the supplemental New Drug Application (sNDA) for Auryxia tablets for the same indication and has set the Prescription Drug User Fee Act (PDUFA) target action date as Nov 6, 2017.  A potential approval should boost sales.. Moreover, shares of the company have outperformed the Medical-Biomed/Genetic Market  in year to date. However, considering that the company is heavily dependent on Auryxia for growth, any further interruption in the supply of Auryxia will hamper its growth trajectory, going forward." (7/17/2017)
  • 3. JMP Securities analysts commented, "Hogan Reward"The expert cited Keryx Biopharmaceuticals (NASDAQ: KERX)'s sulodexide as an example of a development-stage asset that failed such a confirmation in another kidney disease called diabetic nephropathy.The DUET study has rolled over onto the open-label portion, although the active control irbesartan will not be carried forward, thus it may be difficult to detect a treatment benefit."We believe that we will need to wait until year end to determine if the company can convince the FDA that an accelerated approval pathway can meet the agency's needs," analyst Liisa Bayko wrote in a note."Our sensitivity analysis shows that the stock currently reflects the sentiment that accelerated approval is unlikely," (9/8/2016)

Who are some of Keryx Biopharmaceuticals' key competitors?

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the folowing people:

  • Gregory Paul Madison, Chief Executive Officer, Director
  • Scott A. Holmes, Chief Financial Officer, Treasurer
  • Christine A. Carberry, Chief Operating Officer
  • Douglas M. Jermasek, Vice President of Marketing and Strategy
  • Brian R. Adams, General Counsel, Secretary
  • Lora Pike, Senior Director
  • John F. Neylan, Chief Medical Officer
  • John P. Butler, Independent Director
  • Kevin J. Cameron, Independent Director
  • Steven C. Gilman Ph.D., Independent Director

Who owns Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.06%), Baldwin Brothers Inc. MA (0.04%), Creative Planning (0.03%) and Deltec Asset Management LLC (0.02%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes. View Institutional Ownership Trends for Keryx Biopharmaceuticals.

How do I buy Keryx Biopharmaceuticals stock?

Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Keryx Biopharmaceuticals' stock price today?

One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $7.29.

MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  512
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $8.60 (17.97% upside)

Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017Maxim GroupReiterated RatingBuy$9.00MediumView Rating Details
6/17/2017Cowen and CompanyReiterated RatingHoldMediumView Rating Details
1/11/2017Citigroup Inc.UpgradeSell -> Neutral$7.00N/AView Rating Details
11/19/2016FBR & CoReiterated RatingHoldN/AView Rating Details
9/8/2016JMP SecuritiesReiterated RatingOutperformN/AView Rating Details
8/2/2016Raymond James Financial, Inc.Boost Price TargetOutperform$7.00 -> $10.00N/AView Rating Details
8/2/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$9.00 -> $10.00N/AView Rating Details
8/2/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
8/2/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
3/29/2016BTIG ResearchReiterated RatingSell$2.50N/AView Rating Details
2/26/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralN/AView Rating Details
8/10/2015Roth CapitalDowngradeBuy -> Neutral$11.00 -> $6.00N/AView Rating Details
8/7/2015MLV & Co.Reiterated RatingBuy$25.00N/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Earnings by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Earnings History by Quarter for Keryx Biopharmaceuticals (NASDAQ KERX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.18)($0.21)$10.19 million$11.82 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.25)($0.32)$9.65 million$9.53 millionViewListenView Earnings Details
11/9/2016Q316($0.22)($0.39)$5.53 million$6.30 millionViewListenView Earnings Details
8/1/2016Q216($0.28)($0.42)$8.60 million$9.30 millionViewListenView Earnings Details
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details
10/29/2015Q3 2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details
2/27/2015Q414($0.38)($0.44)$1.70 million$0.57 millionViewListenView Earnings Details
11/6/2014Q314($0.27)($0.38)$0.39 million$0.26 millionViewListenView Earnings Details
8/7/2014Q214($0.23)($0.24)$0.28 millionViewListenView Earnings Details
5/8/2014Q114($0.10)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
Current Year EPS Consensus Estimate: $-0.69 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS


Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Insider Ownership Percentage: 3.08%
Institutional Ownership Percentage: 62.26%
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Brian AdamsGeneral CounselSell641$7.67$4,916.47View SEC Filing  
7/5/2017Greg MadisonInsiderSell910$7.67$6,979.70View SEC Filing  
4/28/2017Scott A. HolmesCFOSell1,219$5.89$7,179.91View SEC Filing  
4/24/2017John F. NeylanInsiderSell1,209$5.73$6,927.57View SEC Filing  
4/17/2017Brian AdamsGeneral CounselSell1,090$5.75$6,267.50View SEC Filing  
4/5/2017Brian AdamsGeneral CounselSell642$5.80$3,723.60View SEC Filing  
4/5/2017Greg MadisonInsiderSell911$5.80$5,283.80View SEC Filing  
1/30/2017Brian AdamsGeneral CounselSell6,984$4.65$32,475.60View SEC Filing  
1/30/2017Greg MadisonInsiderSell18,248$4.65$84,853.20View SEC Filing  
1/30/2017Scott A. HolmesCFOSell8,447$4.65$39,278.55View SEC Filing  
1/23/2017John F. NeylanInsiderSell1,428$5.39$7,696.92View SEC Filing  
1/17/2017Brian AdamsVPSell1,265$6.24$7,893.60View SEC Filing  
1/5/2017Brian AdamsVPSell759$6.16$4,675.44View SEC Filing  
1/5/2017Greg MadisonInsiderSell1,077$6.16$6,634.32View SEC Filing  
10/28/2016Scott A. HolmesCFOSell1,237$4.44$5,492.28View SEC Filing  
10/24/2016John F. NeylanInsiderSell1,211$4.72$5,715.92View SEC Filing  
10/17/2016Brian AdamsVPSell1,106$4.86$5,375.16View SEC Filing  
10/5/2016Brian AdamsVPSell647$5.38$3,480.86View SEC Filing  
10/5/2016Greg MadisonInsiderSell917$5.38$4,933.46View SEC Filing  
8/9/2016Greg MadisonInsiderSell1,622$4.22$6,844.84View SEC Filing  
7/29/2016Scott A. HolmesCFOSell4,935$7.36$36,321.60View SEC Filing  
7/25/2016John F. NeylanInsiderSell1,217$7.43$9,042.31View SEC Filing  
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Keryx Biopharmaceuticals (NASDAQ:KERX)
Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateHeadline logoWhat to Expect from Keryx (KERX) this Earnings Season? - July 22 at 5:15 AM logoMaxim Group Reiterates "Buy" Rating for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - July 20 at 6:32 PM logoKeryx Biopharmaceuticals to Host Conference Call of Second Quarter 2017 Financial Results on Thursday, July 27, 2017 - July 19 at 11:19 PM logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 17, 2017 - July 18 at 5:37 AM logoKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Downgraded to "Hold" at Zacks Investment Research - July 17 at 3:28 PM logoKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Given Average Rating of "Hold" by Analysts - July 11 at 8:50 PM logoWhy Keryx Biopharmaceuticals Stock Soared 11.6% Higher in June - July 8 at 7:01 AM logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 5, 2017 - July 6 at 7:00 AM logoKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Expected to Post Quarterly Sales of $14.08 Million - July 2 at 9:27 AM logoKeryx Biopharmaceuticals, Inc. (KERX) Expected to Announce Earnings of -$0.17 Per Share - June 30 at 2:06 PM logoKeryx Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:KERX) : June 19, 2017 - June 19 at 5:08 PM logoKeryx Biopharmaceuticals, Inc. (KERX) Rating Reiterated by Cowen and Company - June 19 at 12:38 AM logoKeryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : June 16, 2017 - June 16 at 7:03 PM logoKeryx Biopharmaceuticals, Inc. (KERX) Given Consensus Recommendation of "Hold" by Analysts - June 16 at 6:32 PM logoKeryx's Path To Profitability Seems Clearer Now - Seeking Alpha - June 13 at 5:55 PM logoKeryx Biopharmaceuticals (KERX) Up 5% Since Earnings Report: Can It Continue? - Nasdaq - June 9 at 11:22 PM logoKeryx Biopharmaceuticals (KERX) Up 5% Since Earnings Report: Can It Continue? - June 9 at 6:21 PM logo Brokerages Anticipate Keryx Biopharmaceuticals (KERX) Will Announce Quarterly Sales of $14.08 Million - June 8 at 11:54 AM logoZacks: Brokerages Anticipate Keryx Biopharmaceuticals (KERX) to Announce -$0.17 EPS - June 6 at 12:38 PM logoKeryx Biopharmaceuticals (KERX) Stock Rating Lowered by ValuEngine - June 2 at 3:08 PM logoKeryx Biopharmaceuticals to Webcast its Presentation at Jefferies' 2017 Healthcare Conference on June 6, 2017 - GlobeNewswire (press release) - June 1 at 7:31 AM logoKeryx Biopharmaceuticals to Webcast its Presentation at Jefferies’ 2017 Healthcare Conference on June 6, 2017 - May 30 at 10:21 AM logoMaxim Group Boosts Keryx Biopharmaceuticals (KERX) Price Target to $9.00 - May 29 at 1:34 PM logoShort Interest in Keryx Biopharmaceuticals (KERX) Declines By 20.3% - May 27 at 7:06 AM logoKeryx Biopharmaceuticals (KERX) Receives Average Rating of "Hold" from Analysts - May 22 at 6:20 PM logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 22, 2017 - May 22 at 5:35 PM logoKeryx Biopharmaceuticals (KERX) Expected to Post Quarterly Sales of $14.08 Million - May 12 at 1:18 PM logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : May 11, 2017 - May 11 at 6:38 PM logoKeryx Biopharmaceuticals (KERX) Expected to Announce Earnings of -$0.19 Per Share - May 10 at 8:24 PM logoKeryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 12:06 PM logoKeryx Biopharmaceuticals (KERX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - May 9 at 12:16 AM logoKeryx Biopharmaceuticals (KERX) Posts Quarterly Earnings Results - May 8 at 11:53 PM logoKeryx Biopharmaceuticals (KERX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - May 8 at 10:26 PM logoKeryx Biopharmaceuticals (KERX) Earns "Buy" Rating from Maxim Group - May 8 at 11:43 AM logoKeryx Biopharma (KERX): Expanding Model And Raising PT - Maxim - - May 8 at 9:21 AM logoKeryx (KERX) Q1 Loss Wider than Expected, Revenues Beat - May 5 at 6:07 PM logoEdited Transcript of KERX earnings conference call or presentation 4-May-17 12:00pm GMT - May 5 at 6:07 PM logoKeryx Biopharma Q1 revenues up 74% - May 4 at 11:18 PM logoKeryx Biopharmaceuticals Announces First Quarter 2017 Financial Results - Yahoo Finance - May 4 at 6:18 PM logoKeryx Biopharma (KERX) Misses Q1 EPS by 1c, Beat on Revenues - - May 4 at 6:18 PM logoKeryx Biopharmaceuticals' (KERX) CEO Greg Madison on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 4 at 6:18 PM logoKeryx Biopharmaceuticals Announces First Quarter 2017 Financial Results - May 4 at 6:18 PM logoInvestor Network: Keryx Biopharmaceuticals, Inc. to Host Earnings Call - May 4 at 6:18 PM logoKeryx (KERX) Posts Wider-than-Expected Q1 Loss, Sales Beat - May 4 at 6:18 PM logoKeryx Biopharma reports 1Q loss - May 4 at 6:17 PM logoPositive Media Coverage Very Likely to Impact Keryx Biopharmaceuticals (KERX) Share Price - May 4 at 12:48 PM logoKeryx Biopharma (KERX) Says Auryxi is Now on Formulary at All Major Medicare Part D Plans - - May 3 at 8:39 PM logoUroGen Pharma Readies $45 Million IPO - May 2 at 10:54 AM logoKeryx Biopharmaceuticals (KERX) Receives "Buy" Rating from Maxim Group - May 1 at 11:24 PM logoSomewhat Positive Media Coverage Very Likely to Impact Keryx Biopharmaceuticals (KERX) Stock Price - May 1 at 7:32 PM



Keryx Biopharmaceuticals (KERX) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff